When ValueAct Capital Partners sees untapped value, it acts. The firm, known for its activist slant, buys large stakes in undervalued
When ValueAct Capital Partners sees untapped value, it acts. The firm, known for its activist slant, buys large stakes in undervalued companies and works with their management to boost performance. Founded in 2000, ValueAct manages some $1.5 billion on behalf of institutional and wealthy individual investors. ValueAct's current portfolio includes stakes in Advanced Medical Optics Inc. (contact lenses; nearly 15%). The company successfully thwarted Advanced Medical Optics' proposed acquisition of Bausch & Lomb in 2008, saying Advanced Medical could not successfully absorb its rival.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Aug 11, 2022
The New York Times
|
Post-IPO Equity | $350.20M | Advertising | Yes |
Dec 10, 2021
Altus Power
|
Post-IPO Equity | $275M | Energy | — |
Aug 7, 2020
AppHarvest
|
Series C | $28M | Agriculture | — |
Jun 4, 2020
Nikola Motor Company
|
Post-IPO Equity | $525M | Automotive | — |
Jan 30, 2020
AppHarvest
|
Series B | $11M | Agriculture | — |